Coating cell-penetrating peptide nanoparticles with polyphosphate masks their positive charge during transit, then enzyme activity at target cells restores the charge to enable cellular uptake.
Charge flip: -22 to +5 mVEnzyme-triggered cleavage of polyphosphate coating flips nanoparticle charge from negative to positive, enabling cell-penetrating peptide uptake
What the researchers found
Polyphosphate coating shifted nanoparticle charge from positive to negative (masking CPP charge). Intestinal alkaline phosphatase cleaved the polyphosphate, causing charge conversion: from -22.2 mV to +5.3 mV for linear-CPP particles and from -19.2 mV to +11.9 mV for loop-CPP particles. Linear-CPP nanoparticles showed higher uptake on Caco-2 intestinal cells than loop-CPP variants. Enzyme inhibition confirmed alkaline phosphatase drives the charge conversion.
Why it matters
The 'polycationic dilemma' — CPPs need a positive charge to enter cells but that charge causes hemolysis and toxicity — has been a major barrier to clinical CPP use. This enzyme-triggered charge-switching approach elegantly solves the problem, potentially enabling safer oral peptide drug delivery.
The numbers in context
Nanocarriers characterized for particle size, polydispersity index, and zeta potential. Both linear-CPP and loop-CPP variants tested.
How the study worked
In vitro study. Linear and loop CPPs were synthesized and attached to nanostructured lipid carriers (NLCs), then coated with polyphosphate. Characterized for size (<270 nm), polydispersity, and zeta potential. Cell viability and hemolysis assessed. Cellular uptake measured by flow cytometry and visualized with confocal microscopy in Caco-2 and HEK cells.
Who was studied
In vitro nanoparticle characterization and cell uptake study
What this study cannot tell us
In vitro only — no in vivo testing of oral delivery or biodistribution. Only two cell lines tested. Hemolysis at ~10% at working concentration may still be a concern. No therapeutic cargo was delivered — purely a delivery platform study. Stability in real GI conditions not tested.
How to read the evidence
Rated preliminary: in vitro proof-of-concept with no in vivo validation or therapeutic cargo testing.
When this study was published
Published in 2024. Addresses a well-known limitation (polycationic dilemma) in cell-penetrating peptide delivery.
The bigger picture
This smart coating approach could make cell-penetrating peptides practical for oral drug delivery, where nanoparticles must survive the GI tract without causing damage before being activated at intestinal cells by alkaline phosphatase.
Questions still open
- Would this charge-switching mechanism work in vivo in the intestinal environment?
- Can therapeutic peptides be loaded into these nanoparticles while maintaining the charge-switching mechanism?
- Would loop CPPs offer advantages over linear CPPs for specific tissue targets?
Common questions
Why can't cell-penetrating peptides be used as drugs already?
How does the smart coating work?
Read the original research
Nanostructured lipid carriers decorated with polyphosphate coated linear and loop cell-penetrating peptides.
International journal of pharmaceutics, 667(Pt A), 124844
Citation
Saleh, Ahmad; Stengel, Daniel; Truszkowska, Martyna; Blanco Massani, Mariana; Kali, Gergely; Bernkop-Schnürch, Andreas. (2024). Nanostructured lipid carriers decorated with polyphosphate coated linear and loop cell-penetrating peptides.. International journal of pharmaceutics, 667(Pt A), 124844. https://doi.org/10.1016/j.ijpharm.2024.124844